Blood-based DNA methylation profiling for the detection of ovarian cancer

Elsevier

Available online 10 September 2022

Gynecologic OncologyHighlights•

Blood-based DNA methylation profiling is feasible in identifying patients with malignant or non-malignant ovarian tumor

Malignant ovarian tumor samples had distinct DNA methylation profile than normal/benign ovarian tissues

Machine learning classifier had a positive predictive value of 93.7% and negative predictive value of 86.8%

AbstractObjectives

Ovarian cancer is a fatal gynecological cancer due to the lack of effective screening strategies at early stage. This study explored the utility of DNA methylation profiling of blood samples for the detection of ovarian cancer.

Methods

Targeted bisulfite sequencing was performed on tissue (n = 152) and blood samples (n = 373) obtained from healthy women, women with benign ovarian tumors, or malignant epithelial ovarian tumors. Based on the tissue-derived differentially-methylated regions, a supervised machine learning algorithm was implemented and cross-validated using the blood-derived DNA methylation profiles of the training cohort (n = 178) to predict and classify each blood sample as malignant or non-malignant. The model was further evaluated using an independent test cohort (n = 184).

Results

Comparison of the DNA methylation profiles of normal/benign and malignant tumor samples identified 1272 differentially-methylated regions, with 49.4% hypermethylated regions and 50.6% hypomethylated regions. Five-fold cross-validation of the model using the training dataset yielded an area under the curve of 0.94. Using the test dataset, the model accurately predicted non-malignancy in 96.2% of healthy women (n = 53) and 93.5% of women with benign tumors (n = 46). For patients with malignant tumors, the model accurately predicted malignancy in 44.4% of stage I-II (n = 9), 86.4% of stage III (n = 59), 100.0% of stage IV tumors (n = 6), and 81.8% of tumors with unknown stage (n = 11). Overall, the model yielded a predictive accuracy of 89.5%.

Conclusions

Our study demonstrates the potential clinical application of blood-based DNA methylation profiling for the detection of ovarian cancer.

Keywords

DNA methylation

Early detection

Ovarian cancer

AbbreviationsDMR

differentially methylated regions

ROC

receiver operating characteristics

View full text

© 2022 Published by Elsevier Inc.

留言 (0)

沒有登入
gif